semaglutide patent expiration us Generic INN equivalents, pharmaceutical information and freedom to operate Looming GLP-1 drug patent expirations

Since its debut by Novo Nordisk in 2026, it stands as the first oral GLP-1 specifically approved for weight loss, unlike Rybelsus, which targets type 2 diabetes

Why Chronic Fatigue Requires Separate Medical Investigation Chronic fatigue has multiple potential roots: thyroid dysfunction, sleep apnea, autoimmune disease, nutrient deficiency, hormonal imbalance, or persistent viral infection

Medication is only one part of medical weight loss

Some patients quit before they hit their goal because they cant function

Hippocampal data is consistent with previous results in aged mice (8.5 months), that detected increased inflammatory genes in response to a high-fat diet in males only (86)